Neurology

Ocrelizumab found to decrease progression of clinical disability.

Sleep disturbances accounted for a quarter of the variance in fatigue among patients with MS.

Each additional year of smoking after multiple sclerosis diagnosis accelerated the time to secondary progressive disease conversion.

MS patients who participate in physical activity more likely to have lower overall amount of brain lesions.

MS advocacy group provides a wide range of services that help patients manage the disease.

Physical and mental impairments prevent MS patients from being engaged in social and community activities.

Participation in social activities found to improve patient quality-of-life.

Exclusively breastfeeding may diminish MS relapse in the first 6 months after giving birth.

Multiple sclerosis advocate discusses the difficulties patients face during treatment.

Researchers still seek to determine if vitamin D can make any difference in the course of MS after onset.

Study finds a pattern of disconnectivity among executive areas of the brain.

Autobiographical memory and episodic future thinking reduced in MS patients.

A list of the most debilitating diseases a patient may face over his or her lifetime was recently curated by Healthcare Business and Technology.

Genetically reduced vitamin D levels could increase susceptibility to MS.

Higher levels of physical activities leads to lower MS relapse rates.

Nano sensor able to catch MS in early development.

Findings could lead to more effective treatments for diseases such as cancer and multiple sclerosis.

Processing speed found to hinder MS patients in everyday life.

Depression and fatigue loom as issues to overcome for patients with multiple sclerosis.

Regular exercise may decrease MS symptoms.

MS comorbidities increase the risk of early mortality.

Salt found to influence immune cells that cause the disease.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

The FDA is warning health care professionals about a rare brain infection seen in multiple sclerosis patients taking fingolimod (Gilenya).

Researchers evaluate solutions to quality-of-life issues.

Decreased connectivity in network specific regions of brain at the core of cognitive changes.

Ocrelizumab may shift MS treatment paradigm.

Topical medications stimulated the regeneration of damaged brain cells.

Glatopa treats patients with relapsing forms of multiple sclerosis.

Sandoz has begun shipping glatiramer acetate (Glatopa), the first FDA-approved generic competitor to Teva's Copaxone multiple sclerosis (MS) drug.